Impact of dermatologic adverse reactions on QOL in oncologic patients: results from a single-center prospective study Cover

.blurhash-client-img { display: none !important; }

Impact of dermatologic adverse reactions on QOL in oncologic patients: results from a single-center prospective study

Romanian Journal of Internal Medicine

Volume 56 (2018): Issue 2 (June 2018)

By: Maria Alexandra Barbu, Cornelia Niţipir, Theodor Voiosu and Călin Giurcăneanu

Open Access

|May 2018

Authors

Maria Alexandra Barbu

m.barbu86@gmail.com

“UMF Carol Davila” School of Medicine, Bucharest

Medical Oncology Department, Elias University Emergency Hospital, Bucharest

Cornelia Niţipir

“UMF Carol Davila” School of Medicine, Bucharest

Medical Oncology Department, Elias University Emergency Hospital, Bucharest

Theodor Voiosu

“UMF Carol Davila” School of Medicine, Bucharest

Călin Giurcăneanu

“UMF Carol Davila” School of Medicine, Bucharest

Dermatooncology Department, Elias University Emergency Hospital, Bucharest

DOI: https://doi.org/10.2478/rjim-2018-0002 | Journal eISSN: 2501-062X | Journal ISSN: 1220-4749

Journal RSS Feed

Language: English

Page range: 96 - 101

Submitted on: Jan 1, 2018

|

Published on: May 17, 2018

Published by: N.G. Lupu Internal Medicine Foundation

In partnership with: Paradigm Publishing Services

Publication frequency: 4 issues per year

Keywords:

EGFR tyrosine kinase inhibitor,

quality of life,

Related subjects:

Clinical medicine,

Internal medicine,

Internal medicine, other,

Gastroenterology,

© 2018 Maria Alexandra Barbu, Cornelia Niţipir, Theodor Voiosu, Călin Giurcăneanu, published by N.G. Lupu Internal Medicine Foundation
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous article Volume 56 (2018): Issue 2 (June 2018)Next article